Transgender adolescents on Medicaid will lose federal funding for hormones, puberty-pausing medications and surgery on 13 October 2026 unless a federal court steps in. Their families have asked it to block the Trump administration rule before it takes effect.

The families' complaint says every major US medical association recognises the treatments as safe and effective when appropriately prescribed. It notes the rule keeps funding for the same drugs and surgeries when used for diagnoses other than gender dysphoria.

Who Is Affected

The Centers for Medicare and Medicaid Services finalised the rule in August. It stops federal reimbursement to states for transition-related care for patients under 18 on Medicaid and under 19 on the Children's Health Insurance Program (CHIP).

The rule leaves mental health services untouched, and children covered by private insurance through an employer are not affected. It does not bar doctors from providing the care or from discussing treatment options with families.

It reaches only federal Medicaid and CHIP money. States can still cover the care with their own funds, and several have taken steps to create alternative state-level funding.

Read more

Mid-Treatment Risks, Legal Fight

Patients already receiving hormone therapy, such as oestradiol and testosterone, by 13 October can keep claiming benefits for six months, until 13 April 2027. Patients who begin hormone therapy after 13 October are not covered by the six-month window.

That six-month tapering period does not apply to puberty-pausing medications or surgical treatments. Federal reimbursement for those ends on 13 October, though surgery is rare among transgender youth.

For families, the dividing line is whether a child was already on hormones by that date. Chris Erchull, senior staff attorney for GLAD, said the administration wants to pull funding for the children's care mid-treatment 'with no plan for what happens to them.'

Erchull said the families made medical decisions 'with their doctors.' The complaint says transgender adolescents 'will lose access to treatments that their physicians have determined are medically indicated.'

Dr Haydée Brown, speaking about Medicaid coverage gaps in general and not this rule, said cancer care depends on timing. When a specialist visit is cancelled, she said, 'the cancer itself does not cancel' and it 'just keeps growing on its own schedule.'

Brown described a diabetic patient with a foot wound who needs care every week or two. If coverage drops and visits stop, an ulcer can become an infection that reaches bone. 'Her body did not politely wait until her Medicaid coverage returned,' she said.

She said a coverage gap 'does not save money' because it moves the bill to the emergency department, where patients often get less specialised treatment. In surgery, she said, the term for this is 'delayed complication,' with harm surfacing weeks later.

Represented by GLAD Law, the National Center for LGBTQ Rights and the ACLU of New Hampshire, the families sued in federal court in New Hampshire. They argue that the rule violates Medicaid law and exceeds the administration's authority.

The suit calls the rule a product of 'political directive,' not 'reasoned deliberation.' The plaintiffs want the court to declare the rule unlawful and bar its implementation.

Erchull said GLAD is asking the court to act quickly 'so these families don't lose the medical care that has enabled their kids to thrive.' Families facing a coverage gap can ask their child's doctor where to continue care.

Community health centres may offer charity care or sliding-scale payment. Groups such as the Trans Youth Emergency Project provide grants and patient support.

Read more